NFKB1 and breast carcinoma: While AMPK has been proposed to be a therapeutic target in breast cancer and inhibitor of many pathways regulated by tyrosine kinase growth factor receptors, our results provide evidence that metformin-activated AMPK directly phosphorylates and inhibits NF-κB activity.